Recent Quotes (30 days)

You have no recent quotes
chg | %

Aralez Pharmaceuticals Inc  

(Public, TSE:ARZ)   Watch this stock  
Find more results for ARZ
5.85
+0.45 (8.33%)
Jan 20 - Close
TSE data delayed by 15 mins - Disclaimer
Currency in CAD
Range 5.71 - 6.23
52 week 4.07 - 8.75
Open 5.71
Vol / Avg. 0.00/11,588.00
Mkt cap 304.88M
P/E     -
Div/yield     -
EPS -1.64
Shares 65.43M
Beta     -
Inst. own 45%
Mar 13, 2017
Q4 2016 Aralez Pharmaceuticals Inc Earnings Release (Estimated) - 9:30AM EDT - Add to calendar
Dec 14, 2016
Aralez Pharmaceuticals Inc at BMO Capital Markets Prescriptions for Success Healthcare Conference - Webcast
Dec 13, 2016
Aralez Pharmaceuticals Inc at Guggenheim Boston Healthcare Conference
Nov 16, 2016
Aralez Pharmaceuticals Inc at Jefferies Healthcare Conference - Webcast
Nov 7, 2016
Q3 2016 Aralez Pharmaceuticals Inc Earnings Call - Webcast
Nov 7, 2016
Q3 2016 Aralez Pharmaceuticals Inc Earnings Release
  

Key stats and ratios

Q3 (Sep '16) 2015
Net profit margin -151.15% -176.63%
Operating margin -144.07% -175.15%
EBITD margin - -175.07%
Return on average assets -29.72% -91.36%
Return on average equity -51.60% -122.83%
Employees 105 -
CDP Score - -

Address

7100 West Credit Ave Suite 101
MISSISSAUGA, ON L5N 0E4
Canada
+1-905-8761118 (Phone)

Website links

Description

Aralez Pharmaceuticals Inc. is a Canada-based specialty pharmaceutical company. The Company focuses on acquiring, developing and commercializing products in cardiovascular, pain and other areas. The Company's products include Fibricor, Cambia, Fiorinal, Fiorinal C, Soriatane, Bezalip SR, NeoVisc, Uracyst, Durela, Proferrin, Resultz and Collatamp G. Its development products include YOSPRALA and Bilastine. Fibricor (fenofibric acid) is indicated as a complementary therapy along with diet for the treatment of hypertriglyceridemia, and as a complementary therapy along with diet to reduce elevated low-density lipoprotein cholesterol (LDL-C), total cholesterol (Total-C), triglycerides (TG) and apolipoprotein B (Apo B). Fibricor is also used to increase high-density lipoprotein (HDL) cholesterol (HDL-C) in patients with hypercholesterolemia or mixed dyslipidemia. Cambia (diclofenac potassium for oral solution) is a non-steroidal anti-inflammatory drug (NSAID).

Officers and directors

Arthur S. Kirsch Independent Chairman of the Board
Age: 63
Andrew I. Koven President, Chief Business Officer
Age: 57
Adrian Adams Chief Executive Officer, Director
Age: 64
Scott J. Charles Chief Financial Officer, Senior Vice President
Age: 41
Jennifer Lou Armstrong Executive Vice President - Human Resources and Administration
Age: 45
Eric L. Trachtenberg Chief Compliance Officer, General Counsel, Corporate Secretary
Age: 42
Mark A. Glickman Chief Commercial Officer
Age: 50
James Patrick Tursi M.D. Chief Medical Officer
Age: 51
Kenneth B. Lee Jr. Lead Independent Director
Age: 68
Jason M. Aryeh Independent Director
Age: 47